IONS (Ionis Pharmaceuticals, Inc.) Stock Market Reviews

crown

search

Read and share opinions on IONS (Ionis Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

IONS

Ionis Pharmaceuticals, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Biogen Completes Acquisition of Alcyone Therapeutics
Nov 14, 2025
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
Nov 14, 2025
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
Nov 13, 2025
Is Olezarsen’s Phase 3 Success Transforming the Investment Case for Ionis Pharmaceuticals (IONS)?
Nov 13, 2025
Ionis to present at upcoming investor conferences
Nov 12, 2025
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
Nov 11, 2025
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
Nov 8, 2025
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
Nov 6, 2025
US$81.91 - That's What Analysts Think Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Is Worth After These Results
Nov 1, 2025
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
Oct 30, 2025
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
Oct 29, 2025
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
Oct 29, 2025
Ionis Pharmaceuticals: Q3 Earnings Snapshot
Oct 29, 2025

Reviews